Discovery Programs

Drug Discovery

Our ML/AI-driven peptide drug discovery platform streaMLine enables us to rapidly develop a peptide hit to a clinically ready candidate with balanced properties and strong IP protection. We handle any type of peptide, and all our work is done in-house to ensure quality and speed.

Why Gubra?

Expertise in peptide drugs
One-stop shop for peptide drug discovery
AI/ML-driven drug discovery platform
Fast delivery of clinical candidates
Proven track record of successful programs

Consult with Lise Biehl Rudkjær

Senior Director, Business Development

Choose the right, trustworthy discovery partner.

ML/AI-driven Peptide Drug Discovery

The streaMLine platform

The streaMLine platform is our ML/AI-driven platform for peptide drug discovery. We use high-throughput AI-driven data analysis and peptide library designs. We optimize several parameters in parallel to quickly obtain the best clinical candidate. All our work is done in-house to ensure its quality.

“

The streaMLine platform enables smarter and faster peptide drug discovery.

Discover our unique ML/AI-driven platform developed by in-house experts.

In-house data generation – high quality & speed

One-stop shop for peptide drug discovery

Peptide synthesis

Customized peptide libraries
4000+ peptides per month
Linear peptides, cyclic peptides
Natural & unnatural amino acids
Half-life extenders, linkers, and fluorophore labeling

In vitro pharmacology

Agonist & antagonist
Internalization
Protein-protein interactions

CMC

Solubility
Physical stability
Chemical stability

Bioanalysis

PK
Metabolite identification
Exposure analysis

In vivo pharmacology

Expert CRO in rodent in vivo pharmacology
Golden-standard models in all indications related to metabolic and fibrotic diseases
Sophisticated in-vivo endpoints
Supported by assay, histology, imaging and NGS facilities